Commentary
Considerations for clinical trials to study cannabinoids in Canadian children with neurologic disorders
Lauren E. Kelly and Anne Junker
CMAJ August 27, 2018 190 (34) E1002-E1003; DOI: https://doi.org/10.1503/cmaj.180605
Lauren E. Kelly
Department of Pediatrics and Child Health (Kelly), Rady College of Medicine, University of Manitoba, Winnipeg, Man.; Clinical Trials Platform (Kelly), George and Fay Yee Centre for Healthcare Innovation, Winnipeg, Man.; Division of Allergy and Immunology (Junker), British Columbia Children’s Hospital, Vancouver, BC; Department of Pediatrics, Faculty of Medicine (Junker), University of British Columbia, Vancouver, BC
PhDAnne Junker
Department of Pediatrics and Child Health (Kelly), Rady College of Medicine, University of Manitoba, Winnipeg, Man.; Clinical Trials Platform (Kelly), George and Fay Yee Centre for Healthcare Innovation, Winnipeg, Man.; Division of Allergy and Immunology (Junker), British Columbia Children’s Hospital, Vancouver, BC; Department of Pediatrics, Faculty of Medicine (Junker), University of British Columbia, Vancouver, BC
MDIn this issue
Article tools
Considerations for clinical trials to study cannabinoids in Canadian children with neurologic disorders
Lauren E. Kelly, Anne Junker
CMAJ Aug 2018, 190 (34) E1002-E1003; DOI: 10.1503/cmaj.180605
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.